CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
INDIGO seeks to improve influenza vaccine effectiveness and accessibility through two novel concepts. It aims to create a cost-effective seasonal vaccine and a pandemic vaccine that addresses current technological limitations.
Despite the availability of flu vaccines for decades, influenza is still an important disease in both developing and developed countries with 500,000 casualties annually and many more people affected.
From a global health perspective, the lack of effectivity, availability, affordability, and accessibility of flu vaccines significantly limits our ability to respond to the seasonal flu every year and in the event of a pandemic.
Currently, a low vaccine effectivity of 40% implies that 60% of vaccin…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Netherlands, Ophemert
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Belgium, Gent
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Denmark, Horsholm
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
France, CHAMPIGNEULLES
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
